

To
The Manager-Listing,
National Stock Exchange of India Limited,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051.

Date: September 30, 2026

Ref: SYMBOL: Q-LINE | ISIN: INE1G2W01011

Subject: Summary of the Proceedings of the 16th Annual General Meeting

Ref: Regulation 30 read with Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Dear Sir/Madam,

Please be informed that the 16th AGM of the Company was held today, i.e., Wednesday, September 30, 2026, at 4:00 p.m. (IST) in physical mode at The Centrum Hotel, Pocket 7, Sector C, Sushant Golf City, Lucknow- 226030, to transact the business as stated in the 16th AGM Notice dated 05th September 2026.

In this regard, please find the enclosed documents.

1. Summary of the proceedings of the 16th AGM of the Company as required under Regulation 30 read with Para A of Schedule – III of the SEBI Listing Regulations as **Annexure A**.
2. Summary of the Chairman's speech as **Annexure B**.

The above information is uploaded on the website of the company: <https://www.qlinebiotech.com>

You are requested to kindly take the above information on record.

For Q-LINE BIOTECH LIMITED

AKHAND
PRATAP
SINGH

Digitally signed by
AKHAND PRATAP
SINGH
Date: 2026.09.30
19:17:59 +05'30'

Akhand Pratap Singh
Company Secretary & Compliance Officer
(M No.: A54065)

Annexure - A
AGM at a Glance

Day	Wednesday
Date	September 30, 2026
Time	04:00 P.M.
Venue	The Centrum Hotel, Pocket 7, Sector C, Sushant Golf City, Lucknow- 226030.
Number of members physically present.	18
Total Number of Members as on record date.	2928

Subject: Summary of the Proceedings of the 16th Annual General Meeting of Q Line Biotech Limited held on Wednesday, September 30, 2026, at 4:00 P.M.

Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with applicable provisions of the Companies Act, 2013 and Secretarial Standard-II on General Meetings, the following is the summary of the proceedings of the 16th Annual General Meeting ("AGM") of Q Line Biotech Limited held on Wednesday, September 30, 2026, at 04:00 P.M.(IST) at The Centrum Hotel, Pocket 7, Sector C, Sushant Golf City, Lucknow- 226030.

The requisite quorum being present, Mr. Saurabh Garg, Chairman & Managing Director of the Company, took the Chair and called the Meeting to order.

The Company Secretary welcomed the Members to the 16th Annual General Meeting and introduced the Directors present on the dais. He also acknowledged the presence of the representatives of the Statutory Auditors, Secretarial Auditor, Scrutinizer and the Senior Management of the Company.

With the consent of the Members present, the Notice convening the AGM, the Directors' Report and the Auditors' Report for the Financial Year ended 31st March, 2026 were taken as read, as the same had already been circulated to the Members.

The Statutory Auditors' Report did not contain any qualification, reservation, adverse remark or disclaimer. The Company Secretary informed the Members that, pursuant to the provisions of Section 108 of the Companies Act, 2013 read with the Companies (Management and Administration) Rules, 2014 and Regulation 44 of the SEBI (LODR) Regulations, 2015, the Company

Q-LINE BIOTECH LIMITED

(Formerly known as "Q-Line Biotech Private Limited.")

Regd. Office: 298-281, Transport Nagar, Kanpur Road, Adj. Transport Nagar Metro Station, Lucknow-226012 (U.P.), INDIA. Tel.: 0522-2433023

Delhi. Office: C-108, Naraina Industrial Area Phase -1, New Delhi, Delhi, 110028. Tel.: 011-45577407

E-mail: compliance@qlinebiotech.com | Website: www.qlinebiotech.com | CIN No.: U74120UP2010PLC042528

had provided the facility of remote e-voting through Central Depository Services (India) Limited (CDSL) to all Members.

The remote e-voting commenced on Sunday, 27th September, 2026 at 9:00 A.M. (IST) and concluded on Tuesday, 29th September, 2026 at 5:00 P.M. (IST).

The Company Secretary further informed the Members that the facility of e-voting at the AGM was made available to those Members who had not cast their votes through remote e-voting.

The Statutory Registers and other documents referred to in the Notice of the AGM were kept open and were available for inspection by the Members throughout the Meeting.

The Chairman then addressed the Members and delivered his speech highlighting, inter alia:

- The operational and financial performance of the Company during the Financial Year 2025-26.
- The Company's growth strategy and future business outlook; and appreciation for the continued trust and support.

The Chairman thereafter invited the Members to seek clarifications and offer their comments on the business items set out in the Notice. No queries were raised by the Members present at the meeting.

The following items of business, as set out in the Notice dated 05th September, 2026, were transacted at the Meeting:

Ordinary Business

1. Adoption of the Standalone and Consolidated Audited Financial Statements of the Company for the Financial Year ended 31st March, 2026 together with the Reports of the Board of Directors and Auditors thereon.
2. Re-appointment of Mr. Ajay Kumar Mahanty (DIN: 07002517), who retires by rotation and, being eligible, offers himself for re-appointment.
3. Re-appointment of Mr. Kuldeep Chowdhry (DIN: 06504620), who retires by rotation and, being eligible, offers himself for re-appointment.

Special Business

4. Ratified the remuneration of the Cost Auditor- M/s P S P & Associates, Cost Accountants (Firm Registration No. 005591).

The Company Secretary informed the Members that M/s MMA & Partners, Practicing Company Secretaries, had been appointed as the Scrutinizer to scrutinize the remote e-voting process and voting conducted at the AGM in a fair and transparent manner.

Company Secretary further informed the Members that the consolidated voting results, along with the Scrutinizer's Report, would be declared within the prescribed time and would be made available on the website of the Company and on the website of CDSL and submitted to the National Stock Exchange (NSE) in accordance with the applicable provisions of the SEBI (LODR) Regulations, 2015.

Q-LINE BIOTECH LIMITED

(Formerly known as "Q-Line Biotech Private Limited.")

Regd. Office: 298-281, Transport Nagar, Kanpur Road, Adj. Transport Nagar Metro Station, Lucknow-226012 (U.P.), INDIA. Tel.: 0522-2433023

Delhi. Office: C-108, Naraina Industrial Area Phase -1, New Delhi, Delhi, 110028. Tel.: 011-45577407

E-mail: compliance@qlinebiotech.com | Website: www.qlinebiotech.com | CIN No.: U74120UP2010PLC042528

Upon conclusion of the business of the Meeting, the Members who had not cast their votes through remote e-voting were provided an additional 30 minutes to cast their votes through the e-voting facility available at the venue. Thereafter, the Meeting concluded at 5:00 P.M. (IST) with a vote of thanks to the Chair.

For Q-LINE BIOTECH LIMITED

AKHAND
PRATAP
SINGH

Digitally signed
by AKHAND
PRATAP SINGH
Date: 2026.09.30
19:18:51 +05'30'

Akhand Pratap Singh
Company Secretary & Compliance Officer
(M No.: A54065)

Annexure B

CHAIRMAN'S ADDRESS

Good afternoon, ladies and gentlemen. I am Saurabh Garg, Chairman & Managing Director of your Company, Q-Line Biotech Limited. It is my pleasure to welcome you to our 16th Annual General Meeting.

I also welcome my fellow Board members, our auditors, scrutineers and advisors, the management team, our employees and all invitees.

This AGM is special. It is our first since Q-Line Biotech listed on the NSE Emerge Platform on 29 May 2026. Listing opens a new phase for us. It also brings greater responsibility to you, our shareholders, and to every stakeholder.

FY 2025-26 was an important year of growth. On a consolidated basis, revenue from operations was ₹341.74 crore. Profit After Tax rose to ₹55.72 crore, from ₹19.21 crore the year before.

More importantly, we made substantial progress in manufacturing. We commissioned our new facility at Lucknow and brought it into commercial operation. It is an investment in the future of Q-Line Biotech.

Going forward, we have six clear priorities.

First, use our capacity. The plant is built. Now we must run it fully and efficiently.

Second, make more of our diagnostic products ourselves, in our own plants. Where it makes commercial and technical sense, we will reduce reliance on external and imported products and strengthen our supply chain.

Third, strengthen and diversify our product portfolio, so our plant and technology can support growth over the long term.

Fourth, expand our installed base and market presence.

Fifth, explore export and CDMO opportunities.

Sixth, keep investing in technology, research, quality systems and regulatory capabilities.

Across all six, one rule holds. In diagnostics, manufacturing growth must go hand in hand with quality, reliability and regulatory compliance. Every product we make must meet the required standards and earn the confidence of laboratories, healthcare professionals and our customers.

We will pursue this growth with financial discipline and strong corporate governance. Our aim is to build a sustainable organisation that creates long-term value for all stakeholders.

I thank our employees, customers, distributors, suppliers, business partners and advisors for their contribution and support.

Above all, I thank you, our shareholders, for your trust in Q-Line Biotech. As a listed company, we will honour that trust with transparency, accountability and disciplined execution.

I will keep the formal Vote of Thanks for the end of the Meeting. I now hand over to our Company Secretary & Compliance Officer, Mr. Akhand Pratap Singh, to take the Meeting forward.

Thank you.

Q-LINE BIOTECH LIMITED

(Formerly known as "Q-Line Biotech Private Limited.")

Regd. Office: 298-281, Transport Nagar, Kanpur Road, Adj. Transport Nagar Metro Station, Lucknow-226012 (U.P.), INDIA. Tel.: 0522-2433023

Delhi. Office: C-108, Naraina Industrial Area Phase -1, New Delhi, Delhi, 110028. Tel.: 011-45577407

E-mail: compliance@qlinebiotech.com | Website: www.qlinebiotech.com | CIN No.: U74120UP2010PLC042528